Back to search
IDH1-mutant Cholangiocarcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which IDH1-mutant Cholangiocarcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which IDH1-mutant Cholangiocarcinoma trials you may qualify forThis phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is…
This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable o…
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has s…
This is an open label, single-arm Phase I study to evaluate the safety, tolerability, PK and preliminary efficacy of AB-218, an oral IDH1 inhibitor, for the tre…